MedPath

Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease

Not Applicable
Terminated
Conditions
Peripheral Arterial Disease
Interventions
Procedure: Long lesion stenting
Procedure: Short spot stenting
Registration Number
NCT03227822
Lead Sponsor
Catharina Ziekenhuis Eindhoven
Brief Summary

Since the length of lesion seems to be negatively associated with stent patency due to restenosis, it is thought that the efficacy of treatment in patients with multiple (\> 1) short (focal; \> 1 and \< 5 cm) SFA lesions can be improved by spot stenting as compared to the use of one long stent. This study proposes to evaluate the endovascular treatment for patients with SFA lesions by comparing two strategies for patients with extensive occlusive SFA disease; 1) short spot (SS) stenting or 2) long lesion (LL) stenting.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
3
Inclusion Criteria
  • PAOD (ABI <0.90 and/or a decline of >0.15 after exercise test), Rutherford category 2, 3 or 4
  • Multiple (>1) short (focal; >1 and < 5 cm) significant stenoses (≥ 50%) and/or occlusions in the superficial femoral artery
  • Eligible for endovascular treatment via short spot stenting and via long lesion stenting according to international guidelines
  • Unilateral occlusive disease
  • Age ≥ 18
Exclusion Criteria
  • Patients with PAOD Rutherford category 5 and 6
  • Impaired inflow due to significant lesions in the arteries proximal to the SFA intended to treat
  • Bilateral lesions with treatment indication
  • Contra-indication for anticoagulant therapy
  • Renal insufficiency (MDRD < 50 ml/min)
  • Life expectancy < 6 months
  • Known contrast allergy
  • Pregnancy
  • Unable to complete a questionnaire in the home language

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Long lesion stentingLong lesion stentingLong lesion stenting
Short spot stentingShort spot stentingShort spot stenting
Primary Outcome Measures
NameTimeMethod
absence of binary restenosis (≥ 50% re-obstruction) of the target lesion without interval clinically driven reintervention1 year
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath